AtriCure

Creating a World Class Platform

J.P. MORGAN
HEALTHCARE CONFERENCE

JANUARY 2023

Forward Looking Statements

This presentation and oral statements made in connection with this presentation contain "forward-looking statements," which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure's expected market opportunity, future business, financial performance, financial condition, and results of operations, and often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "drives," "seek," "believes," "see," "should," "will," "would," "can," "opportunity," "target," "outlook," and similar expressions and the negative versions thereof. Such statements are based only upon current expectations of AtriCure. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates, projections or expectations reflected or contained in the forward-looking statements as a result of various risk factors.

Reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks, uncertainties and other factors include, but are not limited to, those identified at http://www.atricure.com/forward-looking-statements and/or described in AtriCure's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, particularly the "Risk Factors" sections thereof, as filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov.

With respect to all forward-looking statements, AtriCure claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date they are made. AtriCure undertakes no obligation, and does not expect, to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.



Non-GAAP Financial Measures

To supplement AtriCure's condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures as supplemental financial metrics in this presentation.

Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement costs, impairment of intangible asset and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure's financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures, and not to rely on any single financial measure to evaluate our business.



Afib: A Serious Problem

Atrial Fibrillation (Afib) is an irregular heartbeat (or arrhythmia) that affects more than 37 million people worldwide.



8 Million

People estimated to have Afib in the US²



3.5 Million

People estimated to have long-standing persistent Afib in the US³




1 in 4 Adults

Over 40 will develop Afib in their lifetime⁴



Afib: A Serious Problem



Afib
is tied to
higher risk
of stroke,
heart failure,
dementia, and
other health
problems

5X Higher Risk of Stroke⁵

46%Greater Risk of Mortality⁶

>5x

Higher Risk of Heart Failure⁷

AtriCure: Foundation for Success

Innovation

Continuous improvement, increasing pipeline

-\(\frac{1}{\omega}\)-

Clinical Science

Differentiated clinical trials with superior patient outcomes



Expansion

Developing
addressable markets
and expanding
patient impact
globally



Strong history of revenue growth and acceleration from multiple catalysts





Innovative and Expanding Product Portfolio



Continuous innovation to less invasive, simpler to use, more efficient products





Differentiated and Growing Clinical Evidence

Isolator® Synergy **Ablation System** approved by FDA for treatment of persistent or long-standing persistent Afib concomitant to open heart procedures

CONVERGE IDE

Trial: EPi-Sense® **Guided Coagulation** System approved by **FDA** for treatment of long-standing persistent Afib

2021

Future evidence expanding markets, changing standards of care

2011

2020

FROST Study: **Pain Management**

in Post Thoracic Procedures via intercostal Cryoanalgesia

2022

CAPLA Study⁸:

Catheter ablation for persistent Afib - a multicenter randomized study of PVI alone vs. PVI with PWI

HEAL-IST IDE Trial procedure

for treatment of IST

Registries and Studies

Cryoanalgesia **Hybrid Therapy** LAAM IST

LeAAPS IDE Trial prophylactic LAA exclusion for prevention of ischemic stroke in cardiac surgery patients without pre-operative


AF diagnosis



Cardiac Surgery Opportunity (US)

~\$900M

Concomitant Open Procedures (Open Ablation/LAAM)



AtriCure Difference

Innovation

- Isolator Synergy EnCompass[®] Clamp
- AtriClip® platform and expansion of labeling (electrical isolation of LAA)

Science

Isolator® Synergy Ablation System **first medical device with FDA approval** for
treatment of persistent Afib

Education

 Advanced Ablation Courses endorsed by the Society of Thoracic Surgeons

Guidelines⁹


- Surgical Ablation is recommended
- LAA management is reasonable



Hybrid Opportunity (US)

\$2B+ and Growing

Standalone Hybrid Procedures (MIS Ablation/LAAM)



AtriCure Difference

Innovation

- Multiple approaches to treatment: Hybrid AF Therapy + AtriClip[®], DEEP
- EPi-Sense ST approval


Science

 EPi-Sense® System approved by FDA for treatment of long-standing persistent Afib

Education

 Hybrid Training Course cosponsored by the Hearth Rhythm Society

CONVERGE: Long-standing Persistent Afib Patient Analysis




- Superior outcomes with hybrid Convergent procedure when compared to endocardial catheter ablation alone in patients with drug refractory longstanding persistent Afib, with majority of patients experiencing:
 - + Over 100% improvement at 18 months
 - + Over 90% burden reduction at 12 months
 - + Freedom from Afib through 12 months
- Improved EP lab efficiency demonstrated by reduction in endocardial ablation time as a result of adding epicardial ablation
- Emphasizes value of team approach for advanced AF treatment, targeting trigger areas (epi-cardial and endo-cardial) where AF begins



Pain Management Opportunity (US)

~\$1B

Pain Management Procedures (Ablation)



AtriCure Difference

Innovation

- cryoSPHERE® cryoablation probe
- Expanded labeling for Cryo Nerve Block Therapy in adolescents (patients as young as 12 years of age)

Science

- FROST Study
- Can be an important tool in combatting the opioid epidemic – 1 in 7 thoracic surgery patients become reliant upon opioids after their procedure¹⁰

Significant Global Market Opportunity



LOW PENETRATION IN EXISTING MARKETS EXPANSION OPPORTUNITIES IN FOCUS






Financial Results and 2023 Outlook

2023 Guidance

- Worldwide revenue of \$380-387 million (~15-17% annual growth)
- Maintaining Gross Margin
- Improving Adjusted EBITDA to breakeven for 2023





^{* 2022} is Revenue is preliminary and unaudited. 2022 Adjusted EBITDA based on 2022 guidance for a loss of approximately \$4 million.

^{** 2023} Revenue based on midpoint of Revenue guidance range. 2023 Adjusted EBITDA based on guidance to breakeven for 2023.

Commitment to Sustainability

Inaugural sustainability report published



Diversity & Inclusion award recognizing ATRC Board



35th Anniversary of Cox-Maze Procedure



Global headcount passes the millennium mark

– with improvement to diversity metrics!

>800 attendees

At First Women's Cardiac Health Awareness Initiative









We are passionately focused on healing the lives of those affected by Afib and pain after surgery

Large Markets

Addressing an underserved and growing patient population

Strong Portfolio

Existing products and solutions driving consistent growth

Bright Future

Novel therapies supported by growing body of clinical evidence



References and Abbreviations

Note	Reference
1	European Heart Journal – Quality of Care and Clinical Outcomes (2021) 7, 574-582 doi: 10.1093/ehjqcco/qcaa061
2	The American Journal of Cardiology (2013), 112: 1142-1147
3	Medical management estimate: Colilia, et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. Am Journal of Cardiology 2013, 112: 1142-1147
	Persistent patient estimate: Berisso et al Epidemiology of atrial fibrillation: European perspective Clin Epidemiol. 2014; 6: 213–220
4	Lifetime risk for development of atrial fibrillation. Circulation, 110 (2004): 1042-1046. doi: 10.1161/01.CIR.0000140263.20897.42
5	J Geriatr Cardiol. 2016 Oct; 13(10): 880–882, doi: 10.11909/j.issn.1671-5411.2016.10.004
6	Odutayo, A. et al. (2016). Atrial fibrillation and risks of cardiovascular disease, renal disease, and deaths systematic review and meta analysis. BMJ 2016; 354:i4482
7	Santhanakrishnan R et al., "AF Begets Heart Failure and Vice Versa," Circulation, 133 (2016):484-492
8	American Heart Journal. 2022 Jan;243:210-220. doi: 10.1016/j.ahj.2021.09.015.
9	The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation
10	The Society of Thoracic Surgeons, Current News Release (1/30/2018): 1 in 7 Lung Surgery Patients at Risk for Opioid Dependence

Key Abbreviations			
	Afib or AF	Atrial Fibrillation	
	AFL	Atrial Flutter	
	AT	Atrial Tachycardia	
	EP	Electrophysiologist	
	FDA	Food & Drug Administration	
	IDE	Investigational Device Exemption	
	IST	Inappropriate Sinus Tachycardia	
	LAA	Left Atrial Appendage	
	LAAM	LAA Management	
	PVI	Pulmonary Vein Isolation	
	PWI	Posterior Wall Isolation	

